Skip to the line map
Before the Needle

Does Health Insurance Cover Stem Cell Therapy in the United States?

  • Updated November 14, 2026
  • Stop 4 of 4 on the Trials, cost and insurance line

Sometimes, but it depends entirely on which procedure you mean. Blood stem cell transplants for specific diagnoses, such as certain leukemias, are covered by Medicare nationally under defined conditions; commercial insurers and Medicaid programs apply their own written policies. Stem cell or “regenerative” injections for joints, tendons or the spine are a different service, and they can be excluded as investigational. The only reliable answer is a written determination for the exact procedure, diagnosis, provider and plan.

Why the phrase “stem cell therapy” is too broad for a coverage answer

Insurers do not cover categories of biology. They cover services, identified by procedure and diagnosis codes, delivered by a provider in a setting, under the terms of your plan. “Stem cell therapy” can mean:

  • an allogeneic (donor) blood stem cell transplant for leukemia in a hospital transplant unit
  • an autologous (your own) blood stem cell transplant for multiple myeloma
  • a licensed gene therapy made from your own blood stem cells
  • an office injection of a fat-derived or amniotic product into a knee
  • an injection of your own concentrated bone marrow into a hip

These are reviewed under different rules. A yes for the first says nothing about the fourth.

When hematopoietic stem cell transplantation may be covered

For people with Medicare, the national rule is National Coverage Determination 110.23, Stem Cell Transplantation. The version reviewed for this article took effect March 6, 2024. It covers transplantation of blood-forming stem cells from bone marrow, peripheral blood or umbilical cord blood. It does not address joint or spine injections.

Under that NCD, coverage is defined by named indication:

  • Allogeneic transplant, nationally covered: leukemia, leukemia in remission, aplastic anemia, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and myelodysplastic syndromes that meet specified prognostic score criteria.
  • Allogeneic transplant, covered only in an approved study (Coverage with Evidence Development): multiple myeloma, myelofibrosis and severe symptomatic sickle cell disease, each under stated conditions.
  • Autologous transplant, nationally covered: specified situations in acute leukemia, non-Hodgkin lymphoma, neuroblastoma, Hodgkin disease, multiple myeloma and primary AL amyloidosis.
  • Autologous transplant, nationally non-covered: listed situations where evidence was judged insufficient, such as acute leukemia not in remission and solid tumors other than neuroblastoma.

Indications the NCD does not name are left to the local Medicare Administrative Contractor. Commercial insurers and Medicaid programs write their own medical policies, and those policies are not required to match Medicare.

Why experimental orthopedic cell injections often face exclusions

When a plan classifies a service as experimental or investigational, meaning the evidence has not met the plan’s threshold for proven benefit, its exclusion language can be used to deny coverage. For musculoskeletal “stem cell” injections, the evidence picture gives payers a basis for that classification. The American College of Rheumatology’s 2026 guideline summary strongly recommends against stem cell injections for knee and hip osteoarthritis, and FDA has not approved any stem cell product for orthopedic use.

That does not mean every plan words its exclusion the same way, or that every related service is excluded. Read your own plan’s medical policy for the specific product and condition rather than assuming.

FDA approval does not settle coverage either. Approval says a product may be marketed for a labeled use. Medical necessity, prior authorization and payment are separate decisions made by the payer, even for approved products.

How to check a commercial plan, Medicare, or Medicaid policy

  1. Get the codes from the treating facility. Ask for the procedure codes and diagnosis codes they intend to bill. Your insurer cannot answer accurately without them.
  2. Find the plan’s medical policy. If your plan publishes medical policies by topic, search its site for the product type (for example, “orthopedic applications of stem cell therapy” or “bone marrow aspirate concentrate”) and read the coverage criteria and exclusions.
  3. Call member services with a script. Use the checklist below so every call captures the same facts.
  4. Ask whether prior authorization is required. If it is, confirm who will submit the request, and ask for a copy of the decision. Prior authorization is not a guarantee of payment: the claim can still depend on your coverage being active on the date of service, correct billing and the plan’s other terms. Ask separately for a written estimate of your out-of-pocket cost.
  5. For Medicare, check the NCD for the service and ask whether a local coverage determination applies in your region.
  6. For Medicaid, contact your state program or managed care plan; coverage rules vary by state.
  7. If denied, ask for the denial in writing with the policy section cited, and ask how to appeal.

Insurance verification checklist

Field Your notes
Date and time of call
Representative name and reference number
Exact product or procedure name
Procedure codes supplied by the provider
Diagnosis codes supplied by the provider
Is the provider in network?
Is the facility in network?
Is the service covered for this diagnosis?
Is prior authorization required?
Medical policy name and section cited
Your expected cost share (deductible, coinsurance)
Written confirmation requested? Date received

What documents to request before paying

  • a written coverage determination or prior authorization decision for the exact codes
  • confirmation of network status for both the clinician and the facility
  • an itemized estimate of what you will owe if the insurer pays nothing
  • the appeals route and deadline if coverage is denied

If you are paying cash, cost components are explained separately in how much stem cell therapy costs.

Can a clinical trial change what is paid?

It can change who pays for some of the care, but not usually for the investigational product itself. For Medicare, NCD 310.1, Routine Costs in Clinical Trials, current version effective May 27, 2024, covers routine costs in qualifying trials. Routine costs include care you would receive anyway, the items needed to administer the investigational product, monitoring, and care for complications.

The same NCD does not cover:

  • the investigational item or service itself, unless it is covered outside the trial
  • items used only for data collection and not for your clinical management
  • items the sponsor customarily provides free to all participants

A trial also has to qualify. The NCD’s routes include trials funded by agencies such as NIH, trials conducted under an FDA-reviewed IND, and certain other pathways. A study listed on ClinicalTrials.gov does not automatically meet those criteria, and a qualifying route does not mean every cost is paid automatically. The NCD also requires the trial to meet its other conditions, such as studying an item or service that falls within a Medicare benefit category, having therapeutic intent and, for treatment trials, enrolling people with a diagnosed disease, so check the full NCD text and ask for the cost breakdown in writing.

Commercial plans and state Medicaid programs have their own clinical trial rules. Ask both the study team and your insurer, in writing, which services will be billed and to whom. Our guide to finding stem cell clinical trials covers how to locate and read a study record.

Will Medicare cover any stem cell treatment? Medicare covers blood stem cell transplants for the indications and conditions in NCD 110.23, and some others through local contractor decisions. It does not follow that Medicare covers office injections marketed as stem cell treatment for joint pain.

Does FDA approval guarantee that my insurer pays? No. Approval permits marketing for labeled uses. Whether your plan pays depends on its coverage terms, medical necessity criteria and authorization rules.

Status block: what to recheck

Medicare NCD versions and commercial medical policies are revised. The CMS pages cited here were read on November 14, 2026; on that day the NCD 110.23 version table listed Version 2, effective March 6, 2024, as the current version with no end date, although the page also displayed a generic “not the latest version” prompt and later revision-history entries that describe transmittal updates rather than a new numbered version. Recheck the current version before relying on any specific covered indication.

Every stop on the Trials, cost and insurance line

  1. What Do Phase 1, 2, and 3 Mean in Stem Cell Clinical Trials?
  2. How to Find Stem Cell Clinical Trials on ClinicalTrials.gov
  3. How Much Does Stem Cell Therapy Cost in the United States?
  4. Does Health Insurance Cover Stem Cell Therapy in the United States?

Reader comments

Leave a note on this stop

Your email address will not be published. Required fields are marked *